 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123 |
- || trifarotene (CD5789) / Galderma Laboratories
New Drug Trials Snapshot available for Aklief (trifarotene): https://t.co/JMkPdTkqqF. (Twitter) - Oct 17, 2019
- || trifarotene (CD5789) / Galderma Laboratories
FDA OKs Trifarotene, First New Retinoid Acne Cream in 20 Years https://t.co/e4QATM7XjD via @medscape (Twitter) - Oct 15, 2019
- || trifarotene (CD5789) / Galderma Laboratories
FDA OKs Trifarotene, First New Retinoid Acne Cream in 20 Years https://t.co/ezP7YkVT3J via @medscape (Twitter) - Oct 9, 2019
- || trifarotene (CD5789) / Galderma Laboratories
FDA OKs Trifarotene, First New Retinol Acne Cream in 20 Years https://t.co/kwZW0tbfqP via @medscape (Twitter) - Oct 4, 2019
- | Aklief (trifarotene) / Galderma
Enrollment closed: Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris (clinicaltrials.gov) - Jul 30, 2019
P3, N=40, Active, not recruiting, Sponsor: Galderma R&D
Recruiting --> Active, not recruiting
- | trifarotene (CD5789) / Galderma Laboratories
Journal: Topical trifarotene: a new retinoid. (Pubmed Central) - Jun 22, 2019
Recruiting --> Active, not recruiting No abstract available
- | Aklief (trifarotene) / Galderma
New P3 trial: Participant Reported Outcomes With Use of Trifarotene 50 μg/g Cream in the Treatment of Moderate Facial and Truncal Acne Vulgaris (clinicaltrials.gov) - Apr 16, 2019
P3, N=40, Recruiting, Sponsor: Galderma R&D
- | Aklief (trifarotene) / Galderma
New P2 trial: A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis (clinicaltrials.gov) - Nov 13, 2018
P2, N=120, Not yet recruiting, Sponsor: Mayne Pharma International Pty Ltd
- ||||||| Aklief (trifarotene) / Galderma
Trial completion: Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Dec 21, 2017
P3, N=1208, Completed, Sponsor: Galderma R&D
No abstract available Active, not recruiting --> Completed
- ||||| Aklief (trifarotene) / Galderma
Enrollment closed: Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Sep 1, 2017
P3, N=1200, Active, not recruiting, Sponsor: Galderma R&D
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||||| Aklief (trifarotene) / Galderma
Trial completion: CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris (clinicaltrials.gov) - Jun 1, 2017
P3, N=455, Completed, Sponsor: Galderma R&D
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||| Aklief (trifarotene) / Galderma
Trial primary completion date: Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Apr 19, 2017
P3, N=1200, Recruiting, Sponsor: Galderma R&D
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Jan 2018
- ||||||| Aklief (trifarotene) / Galderma
Trial completion: Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Feb 28, 2017
P3, N=1212, Completed, Sponsor: Galderma R&D
Trial primary completion date: Mar 2017 --> Jan 2018 Recruiting --> Completed
- ||||| Aklief (trifarotene) / Galderma
Enrollment closed: CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris (clinicaltrials.gov) - Apr 29, 2016
P3, N=455, Active, not recruiting, Sponsor: Galderma R&D
Recruiting --> Completed Recruiting --> Active, not recruiting
- |||||| Aklief (trifarotene) / Galderma
Enrollment open: Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Feb 8, 2016
P3, N=1200, Recruiting, Sponsor: Galderma R&D
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Aklief (trifarotene) / Galderma
Enrollment open: Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Jan 20, 2016
P3, N=1200, Recruiting, Sponsor: Galderma R&D
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Aklief (trifarotene) / Galderma
New P3 trial: Efficacy and Safety of CD5789 (Trifarotene) 50μg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Oct 2, 2015
P3, N=1200, Not yet recruiting, Sponsor: Galderma R&D
- |||||||||| Aklief (trifarotene) / Galderma
New P3 trial: Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris (clinicaltrials.gov) - Sep 22, 2015
P3, N=1200, Not yet recruiting, Sponsor: Galderma R&D
- |||||| Aklief (trifarotene) / Galderma
Enrollment open: CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris (clinicaltrials.gov) - Mar 31, 2015
P3, N=500, Recruiting, Sponsor: Galderma R&D
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Aklief (trifarotene) / Galderma
Trial completion: CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Mar 17, 2015
P1, N=11, Completed, Sponsor: M.D. Anderson Cancer Center
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- ||||| Aklief (trifarotene) / Galderma
Trial initiation date, Trial primary completion date: CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris (clinicaltrials.gov) - Jan 22, 2015
P3, N=500, Not yet recruiting, Sponsor: Galderma R&D
Active, not recruiting --> Completed Initiation date: Oct 2014 --> Feb 2015 | Trial primary completion date: Oct 2016 --> Feb 2017
- |||||||||| Aklief (trifarotene) / Galderma
New P3 trial: CD5789 (Trifarotene) Long Term Safety Study on Acne Vulgaris (clinicaltrials.gov) - Jul 14, 2014
P3, N=500, Not yet recruiting, Sponsor: Galderma R&D
- Aklief (trifarotene) / Galderma
Enrollment closed: CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Apr 2, 2014
P1, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Oct 2014 --> Feb 2015 | Trial primary completion date: Oct 2016 --> Feb 2017 Recruiting --> Active, not recruiting
- |||| Aklief (trifarotene) / Galderma
Trial completion: Dose Range Study of CD5789 in Acne Vulgaris (clinicaltrials.gov) - Oct 10, 2013
P2, N=304, Completed, Sponsor: Galderma
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Aklief (trifarotene) / Galderma
New P2 trial: Efficacy and safety of CD5789 in skin keratinization disorders (EUDRACT) - Aug 27, 2013
P2, N=60, Ongoing, Sponsor: Galderma R&D SNC
- | Aklief (trifarotene) / Galderma
New P1 trial: CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) (clinicaltrials.gov) - Mar 3, 2013
P1, N=15, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
- ||||| Aklief (trifarotene) / Galderma
New P2 trial: Dose Range Study of CD5789 in Acne Vulgaris (clinicaltrials.gov) - Jun 10, 2012
P2, N=304, Completed, Sponsor: Galderma